Arrhythmic burden in patients with new-onset persistent left bundle branch block after transcatheter aortic valve replacement: 2-year results of the MARE study.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
05 02 2021
Historique:
received: 24 02 2020
accepted: 10 07 2020
pubmed: 22 10 2020
medline: 10 8 2021
entrez: 21 10 2020
Statut: ppublish

Résumé

We determined the incidence and type of arrhythmias at 2-year follow-up in patients with new-onset persistent left bundle branch block (LBBB) following transcatheter aortic valve replacement (TAVR). Multicentre prospective study including 103 consecutive patients with new-onset persistent LBBB post-TAVR (SAPIEN XT/3: 53; CoreValve/Evolut R: 50). An implantable cardiac monitor (Reveal XT, Reveal Linq) was implanted before hospital discharge and patients had continuous monitoring for up to 2 years. Arrhythmic events were adjudicated in a central core lab. 1836 new arrhythmic events (tachyarrhythmias: 1655 and bradyarrhythmias: 181) occurred at 2 years. Of these, 283 (15%) occurred beyond 1 year (tachyarrhythmias 212, bradyarrhythmias 71) in 33 (36%) patients, without differences between valve type. Most late (>1 year) arrhythmic events were asymptomatic (94%) and led to a treatment change in 17 (19%) patients. A total of 71 late bradyarrhythmias [high-degree atrioventricular block (HAVB): 3, severe bradycardia: 68] were detected in 17 (21%) patients. At 2 years, 18 (17%) patients had received a permanent pacemaker (PPM) or implantable cardiac-defibrillator. PPM implantation due to HAVB predominated in the early phase post-TAVR, with only 1 HAVB event requiring PPM implantation after 1 year. Patients with new-onset LBBB post-TAVR exhibited a very high burden of arrhythmic events within the 2 years post-procedure. While new tachyarrhythmic events were homogeneously distributed over time, the vast majority of new HAVB episodes leading to PPM implantation occurred early after the procedure. These results should help to guide the management of this challenging group of patients. (clinicaltrials.gov: NCT02153307).

Identifiants

pubmed: 33083813
pii: 5934086
doi: 10.1093/europace/euaa213
doi:

Banques de données

ClinicalTrials.gov
['NCT02153307']

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-263

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Guillem Muntané-Carol (G)

Department of Cardiology, Quebec Heart & Lung Institute, Laval University, 2725 Ch Ste-Foy, Quebec City, G1V 4G5, Quebec, Canada.

Marina Urena (M)

Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Höpital Bichat-Claude Bernard, Paris, France.

Luis Nombela-Franco (L)

Department of Cardiology, Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Ignacio Amat-Santos (I)

Department of Cardiology, Hospital Universitario de Valladolid, Valladolid, Spain.

Neal Kleiman (N)

Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.

Antonio Munoz-Garcia (A)

Department of Cardiology, Hospital Virgen de la Victoria, Málaga, Spain.

Felipe Atienza (F)

Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Vicenç Serra (V)

Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Marc W Deyell (MW)

Division of Cardiology and Centre for Cardiovascular Innovation, University of British Columbia, St Paul's hospital, Vancouver, British Columbia, Canada.

Gabriela Veiga-Fernandez (G)

Department of Cardiology, Hospital Marques de Valdecilla, Santander, Spain.

Jean-Bernard Masson (JB)

Department of Cardiology, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada.

Victoria Canadas-Godoy (V)

Department of Cardiology, Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.

Dominique Himbert (D)

Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Höpital Bichat-Claude Bernard, Paris, France.

Javier Castrodeza (J)

Department of Cardiology, Hospital Universitario de Valladolid, Valladolid, Spain.

Jaime Elizaga (J)

Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Jaume Francisco Pascual (J)

Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

John G Webb (JG)

Division of Cardiology and Centre for Cardiovascular Innovation, University of British Columbia, St Paul's hospital, Vancouver, British Columbia, Canada.

Jose M de la Torre Hernandez (JM)

Department of Cardiology, Hospital Marques de Valdecilla, Santander, Spain.

Lluis Asmarats (L)

Department of Cardiology, Quebec Heart & Lung Institute, Laval University, 2725 Ch Ste-Foy, Quebec City, G1V 4G5, Quebec, Canada.

Emilie Pelletier-Beaumont (E)

Department of Cardiology, Quebec Heart & Lung Institute, Laval University, 2725 Ch Ste-Foy, Quebec City, G1V 4G5, Quebec, Canada.

Francois Philippon (F)

Department of Cardiology, Quebec Heart & Lung Institute, Laval University, 2725 Ch Ste-Foy, Quebec City, G1V 4G5, Quebec, Canada.

Josep Rodés-Cabau (J)

Department of Cardiology, Quebec Heart & Lung Institute, Laval University, 2725 Ch Ste-Foy, Quebec City, G1V 4G5, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH